Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Development of Denovo DSA after One Year Post Kidney Transplant and Clinical Outcomes in Patient on Steroid Free Immunosupression
A. Sharfuddin, M. Yaqub, D. Mishler, W. Goggins, T. Taber, O. Adebiyi.
Division of Renal Disease and Hypertension, Indiana University Health Transplant Program, Indianapolis, IN.
Background: Development of Denovo donor specific antibodies (DnDSA) has been associated with poor allograft outcomes in few studies. However, there is scarcity of data evaluating…
2018 American Transplant Congress
IL-6 Inhibition with Tocilizumab to Promote Tregs and Control Renal Graft Inflammation: A Prospective Randomized Controlled Trial
S. Chandran, J. Leung, Z. Laszik, Q. Tang, C. Hu, M. Sarwal, F. Vincenti.
UCSF, San Francisco.
Background: IL-6, a proinflammatory cytokine & key regulator of Treg/Th17, is strongly associated with renal graft rejection. In theory, IL-6 blockade with tocilizumab (TCZ), a…
2018 American Transplant Congress
All DQ DSA May Not Be Equal: Comparing Outcomes between De Novo DQ DSA Specificities
M. Everly,¹ K. Briley,² A. Nguyen,¹ V. Jucaud,¹ A. Maldonado,³ C. Haisch,² P. Bolin,² S. Kendrick,⁴ H. Jones,⁴ K. McLawhorn,⁴ D. Leeser,² L. Rebellato.²
¹Terasaki Research Institute, Los Angeles; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
It is not known if development of de novo DSA (dnDSA) to different HLA-DQ mismatches (serological) are associated with equal risk to a patient's allograft…
2018 American Transplant Congress
Hospital Readmissions Following ABO-Incompatible Live Donor Kidney Transplantation: A National Study
B. Orandi,¹ X. Luo,² S. Bae,² E. King,² J. Garonzik-Wang,² D. Segev.²
¹UCSF, San Francisco; ²Hopkins, Baltimore.
30% of kidney transplant recipients are readmitted in the first month post-transplant. ABO-incompatible (ABO-I) recipients constitute a unique subpopulation that might be at higher readmission…
2018 American Transplant Congress
Serial Monitoring of Resolution of Sub-Clinical Acute Rejection (subAR) in Kidney Transplant Recipients (KTR) Using a Gene Expression Profile (GEP)
L. Zhao,¹ B. Armstrong,² J. Friedewald,¹ T. Whisenant,³ S. Kurian,³ R. Heilman,⁴ E. Poggio,⁵ C. Marsh,³ P. Baliga,⁶ N. Bridges,⁷ J. Odim,⁷ M. Brown,⁷ D. Ikle,² J. Charette,¹ S. Brietigam,¹ N. Sustento-Reodica,¹ M. Kandpal,¹ D. Salomon,³ M. Abecassis.¹
¹Northwestern, Chicago; ²Rho, Chapel Hill; ³Scripps, La Jolla; ⁴Mayo AZ, Scottsdale; ⁵Cleveland Clinic, Cleveland; ⁶MUSC, Charleston; ⁷NIAID, Bethesda.
BACKGROUNDSubAR can currently only be detected using surveillance biopsies (SBx) and is associated with poor long-term graft outcomes. Response to treatment is difficult to assess.…
2018 American Transplant Congress
Circulating Wnt Pathway Factors Are Non-Invasive Biomarkers of Transplant Vascular Injury
M. Seifert,¹ A. Malone,² L. Boohaker,¹ J. Gaut,² S. Jain,² D. Brennan,^2,3 R. Mannon.¹
¹UAB School of Medicine, Birmingham; ²Washington University, St. Louis; ³Johns Hopkins University, Baltimore.
Purpose: Transplant vascular injury (TVI) is a major cause of renal allograft failure and is resistant to treatment. Non-invasive pathogenic biomarkers of TVI would provide…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
ABO-Incompatibility Lower Incidence of DSA-Induced Antibody-Mediated Rejection
D. Lee,¹ B. Kim,¹ J. KIm,¹ I. KIm,¹ M. Jeon.¹
¹Nephrology, Medicine, Maryknoll General Hospital, Busan, Republic of Korea; ²Laboratory Medicine, Maryknoll General Hospital, Busan, Republic of Korea; ³Surgery, Maryknoll General Hospital, Busan, Republic of Korea; ⁴Urology, Maryknoll General Hospital, Busan, Republic of Korea; ⁵Pathology, Maryknoll General Hospital, Busan, Republic of Korea.
Introduction:Donor-specific anti-HLA antibody (DSA) and Anti-ABO antibody are major barriers for successful kidney transplantation. Limited data are available about the existences of both DSA and…
2018 American Transplant Congress
Non Active Desensitization Protocol: Improving Access to Kidney Transplant for Hyperimmunized Patients
S. Le Bot,¹ F. Delbos,² C. Garandeau,¹ S. Malard Castagnet,² A. Cesbron,² M. Hourmant.¹
¹Nephrology and Transplantation, CHU Hôtel Dieu, Nantes, France; ²Laboratoire HLA, Etablissement Français du Sang, Nantes, France.
Hyperimmunized patients have a bad access to renal transplantation, despite national priority programs and active desensitization protocols. After having noticed that some HLA antibodies decreased…
2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
I. Helanterä,¹ F. Ortiz,² R. Loginov,³ L. Mannonen,³ M. Lempinen,¹ I. Lautenschlager.³
¹Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland; ²Nephrology, Helsinki University Hospital, Helsinki, Finland; ³Virology, Helsinki University Hospital, Helsinki, Finland.
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…